SBIR/STTR Research Award

Development of a Genotoxicity Assay using Duplex Sequencing

Award identifier ebf546f5db339eb97074a5e49938f209a315b1ee6a3f0de2b72375571c745cb8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,797

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
TWINSTRAND BIOSCIENCES INC
Proposal award date
2019-07-15
Contract end date
2020-01-31
UEI
HPY9BJWV8X31
Solicitation number
PA18-574
Topic code
NIEHS

Research abstract

A RAPIDACCURATE AND MECHANISTICALLY INFORMATIVE GENOTOXICITY ASSAY USINGDUPLEX SEQUENCING Genotoxicity testingthe evaluation of chemicals for the potential to induce DNA mutations increasing human cancer riskis a crucial part of development of drugscosmetics and other productsBut the available battery of mutagenicity assays forces frustrating trade offs between performance and convenienceAnd while existing tests can detect mutagenesismost provide no insight into mechanism of actionA more convenient accuraterapidand mechanistically informative assay is needed to speed drug and other chemical development and better detect threats to human healthThis SBIR grant application proposes to develop an end to end laboratory kit and software based genotoxicity testing product using Duplex Sequencingthe most accurate DNA sequencing technology in existenceBecause Duplex Sequencing can detect ultra low frequency mutations at levels below one in ten millionit can identify a chemical as mutagenic within weeks of exposureBecause it relies on a simple workflow that only requires extracted DNA as an inputit can be deployed far more widely than existing in vivo assaysAnd because it assesses not just mutation frequency but also the identities of the specific mutations inducedDuplex Sequencing will be the only genotoxicity test that reveals chemicalstrinucleotidemutational signatureswhich can implicate specific mutagenic mechanismsthus enabling strategic redesign of a mutagenic but otherwise promising drugWe have generated strong proof of principle resultsbut substantial work is needed to translate our experimental assay into an off the shelf product that customers can easily adoptIn this proposal we will optimize and validate a user friendly Duplex Sequencing genotoxicity assay in preparation for commercializationIn Phase I we will construct Duplex Sequencing panels for measurement of genotoxicity in ratsmice and humansand evaluate their performanceIn Phase II we will optimize the assay s protocols and reagentsbuild and deploy cloud based software allowing biologists to easily render Duplex Sequencing outputs into interpretable resultsand validate our assay in animal and human cell line models over diverse mutagensinclusive of assessing their mutational signaturesGenotoxicity testing is a vital discipline that has relied on antiquated techniques for too longThe speedaccuracy and information content of Duplex Sequencing promises a radical improvement to the status quoWe expect this convenient and easy to implement test to find rapid uptake among drug companies searching for betterearlier genotoxicity readoutsin CROs excited for a broadly applicable assay they can offer their customers and among academicslooking to push the envelope of their fields Project Narrative Although multiple assays for mutagenicity testing existnone is sufficiently fastaccurate and simple enough for widespread useThis project proposes to use Duplex Sequencing to develop a convenient and robustly performing kit and software genotoxicity testing product that can directly measure the frequency and identity of mutations arising in mutagen treated model organisms and cell linesThis assay will also provide the field a new capabilityby measuring trinucleotide mutation signaturesit will be the first genotoxicity assay able to routinely inform on mutagenic mechanism of action

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

7 SBIR/STTR records share this UEI (2017–2023). Reported award amounts total $9,679,058. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.